Literature DB >> 10208281

Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note.

U Wüllner1, J Kornhuber, M Weller, J B Schulz, P A Löschmann, P Riederer, T Klockgether.   

Abstract

We studied the substantia nigra of three Parkinson's disease (PD) patients and three age-matched individuals by in situ DNA-end labeling (ISEL) and immunohistochemistry for the apoptosis regulating proteins Bcl-2, Bax and Bcl-x on 50 consecutive sections per patient. No melanin-containing cell was identified with typical apoptotic changes in either patient or control substantia nigra. With prolonged reaction-time the terminal transferase-mediated DNA-end labeling revealed a signal in 2.0 +/-1.2% melanin-containing cells in PD compared to 1.3 +/-1.1% in control. This difference did nor reach statistical significance and no condensation or margination of the chromatin was evident. No significant changes of any of the apoptosis regulating proteins were apparent in PD substantia nigra. These findings do not support the hypothesis that apoptosis plays a central role in the pathogenesis of PD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208281     DOI: 10.1007/s004010051005

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  17 in total

1.  Review of apoptosis vs. necrosis of substantia nigra pars compacta in Parkinson's disease.

Authors:  R M Kostrzewa
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

2.  Differential nigral expression of bcl-2 protein family in the pure and common forms of Dementia with Lewy bodies: relevance for dopaminergic neuronal vulnerability.

Authors:  M Saldaña; E Aguilar; M Bonastre; C Marin
Journal:  J Neural Transm (Vienna)       Date:  2007-07-04       Impact factor: 3.575

3.  Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains.

Authors:  B O Evert; I R Vogt; C Kindermann; L Ozimek; R A de Vos; E R Brunt; I Schmitt; T Klockgether; U Wüllner
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

4.  Mitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases.

Authors:  Lee J Martin
Journal:  Pharmaceuticals (Basel)       Date:  2010

5.  Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice.

Authors:  Marina Yamada; Kotaro Kida; Willington Amutuhaire; Fumito Ichinose; Masao Kaneki
Journal:  Biochem Biophys Res Commun       Date:  2010-10-19       Impact factor: 3.575

6.  Multiplex three-dimensional brain gene expression mapping in a mouse model of Parkinson's disease.

Authors:  Vanessa M Brown; Alex Ossadtchi; Arshad H Khan; Simon Yee; Goran Lacan; William P Melega; Simon R Cherry; Richard M Leahy; Desmond J Smith
Journal:  Genome Res       Date:  2002-06       Impact factor: 9.043

7.  Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  O Eberhardt; R V Coelln; S Kugler; J Lindenau; S Rathke-Hartlieb; E Gerhardt; S Haid; S Isenmann; C Gravel; A Srinivasan; M Bahr; M Weller; J Dichgans; J B Schulz
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

8.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

9.  An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

Authors:  Todd B Sherer; Ranjita Betarbet; Amy K Stout; Serena Lund; Melisa Baptista; Alexander V Panov; Mark R Cookson; J Timothy Greenamyre
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

Review 10.  Programmed cell death in Parkinson's disease.

Authors:  Katerina Venderova; David S Park
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.